SAN DIEGO--(BUSINESS WIRE)--Jan. 25, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced the appointment of James (Randy) R. Owen,
M.D., as Senior Vice President, Clinical Development and Chief Medical
Officer. Dr. Owen will be responsible for evolving and executing the
clinical development programs for ACADIA’s product candidates and report
to Serge Stankovic, M.D., M.S.P.H., ACADIA’s Executive Vice President,
Head of Research and Development.

“Randy brings significant expertise in clinical research and development
along with a deep knowledge of CNS science,” said Steve Davis, ACADIA’s
President and Chief Executive Officer. “He has led the development and
approval of important therapeutics in CNS and will be a valued addition
to the ACADIA team as we seek to help patients who suffer from serious
neurological and psychiatric disorders.”

Dr. Owen most recently served as Vice President, U.S. Clinical Affairs
at Lundbeck LLC from 2010 to 2016. During his tenure, his team of
medical experts and scientists made significant contributions in drug
development across a wide range of neurological and psychiatric
disorders, including innovative development programs in schizophrenia,
Alzheimer’s disease and stroke, as well as pediatric and adult orphan
indications. Prior to joining Lundbeck, Dr. Owen served as Group
Director, Global Clinical Research at Bristol-Myers Squibb Company where
he co-led the life-cycle management of Abilify® during a
period of product extensions in psychiatric indications in the United
States and Europe. Dr. Owen received his B.A. at Haverford College and
his M.D. at East Tennessee State University, Quillen College of
Medicine. He completed his residency at Emory University and is board
certified in psychiatry.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA has a pipeline of product
candidates led by NUPLAZID™ (pimavanserin), for which we have submitted
a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA
and which has the potential to be the first drug approved in the United
States for this condition. The FDA has classified the NUPLAZID NDA as
having Priority Review status. Pimavanserin is also in Phase II
development for Alzheimer’s disease psychosis and has successfully
completed a Phase II trial in schizophrenia. ACADIA also has
clinical-stage programs for glaucoma and, in collaboration with
Allergan, Inc., for chronic pain. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the potential for NUPLAZID
(pimavanserin) to be the first drug approved in the United States for
Parkinson’s disease psychosis (PDP) and the potential timing of such
approval, if approved at all, by the FDA; the potential contributions of
Dr. Owen to ACADIA; the progress, timing and results of ACADIA’s drug
discovery and development programs, either alone or with a partner,
including the progress and expected timing of clinical trials; and the
benefits to be derived from ACADIA’s product candidates, including
pimavanserin. These statements are only predictions based on current
information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including
the risks and uncertainties inherent in drug discovery, development,
approval and commercialization, and collaborations with others, and the
fact that past results of clinical trials and past regulatory decisions
may not be indicative of future trial results or future regulatory
decisions, respectively. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year ended
December 31, 2014 as well as ACADIA’s subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.